Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
First-Line Pembrolizumab–Axitinib Benefits In Advanced RCC Maintained With Longer Follow-Up
CDK4/6 Inhibitor Benefits Confirmed For Selected Metastatic Breast Cancer Patients
Abemaciclib Improves Invasive DFS For Select High-Risk Early Breast Cancer Patients
AURA3 Fails To Demonstrate OS Benefit For Osimertinib
Veliparib–Chemotherapy ‘A Compelling Option’ For BRCA-Mutated Breast Cancer
E-Learning
ESMO E-Learning: Multimodular Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Next Generation Drugs in Kidney Cancer
ESMO E-Learning: Management of Cancer Associated Thrombosis
ESMO E-Learning: Treatment of Locally Advanced NSCLC with Chemo-radiotherapy
Meeting resources
Acquired resistance to NTRK inhibitors and development of inhibitors targeting resistance mutations
Presenter: U. N. Lassen, DK
Session: SESSION 6 – Clinical development of NTRK inhibitors – Part 2
Resources:
Slides
Webcast
Present results with larotrectinib
Presenter: U. N. Lassen, DK
Session: SESSION 4 – Clinical development of NTRK inhibitors – Part 1
Resources:
Slides
Webcast
Multi Kinases inhibitors with NTRK as a possible target
Presenter: M. Tahara, JP
Session: SESSION 4 – Clinical development of NTRK inhibitors – Part 1
Resources:
Slides
Webcast
242MO - Sarcopenia as A Predictor of Overall Survival in Patients with Ovarian Cancer Undergoing Chemotherapy : A Systematic Review and Meta-Analysis
Presenter: Vika Damay
Session: Mini oral session on Gynaecological tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.